[Comparison of etoposide combined with G-CSF and cyclophosphamide combined with G-CSF in mobilization of autologous peripheral hematopoietic stem cells in patients with newly diagnosed multiple myeloma].
作者信息
Li J, Zhang R, Chen L J, Qu X Y, Lu H, Li J Y, Jin Y Y
机构信息
Department of Hematology, the First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, Nanjing 210029, China.
出版信息
Zhonghua Xue Ye Xue Za Zhi. 2022 Sep 14;43(9):781-784. doi: 10.3760/cma.j.issn.0253-2727.2022.09.012.
Abstract
摘要
相似文献
1
[Comparison of etoposide combined with G-CSF and cyclophosphamide combined with G-CSF in mobilization of autologous peripheral hematopoietic stem cells in patients with newly diagnosed multiple myeloma].依托泊苷联合粒细胞集落刺激因子与环磷酰胺联合粒细胞集落刺激因子在初诊多发性骨髓瘤患者自体外周造血干细胞动员中的比较
Zhonghua Xue Ye Xue Za Zhi. 2022 Sep 14;43(9):781-784. doi: 10.3760/cma.j.issn.0253-2727.2022.09.012.
2
Cyclophosphamide plus granulocyte-colony stimulating factor for hematopoietic stem cell mobilization in patients with multiple myeloma.环磷酰胺联合粒细胞集落刺激因子用于多发性骨髓瘤患者造血干细胞动员
J Clin Apher. 2016 Oct;31(5):423-8. doi: 10.1002/jca.21421. Epub 2015 Sep 5.
3
[Comparison of etoposide combined with G-CSF and cyclophosphamide combined with G-CSF in the mobilization of autologous peripheral blood stem cells in patients with multiple myeloma].依托泊苷联合粒细胞集落刺激因子与环磷酰胺联合粒细胞集落刺激因子用于动员多发性骨髓瘤患者自体外周血干细胞的比较
Zhonghua Xue Ye Xue Za Zhi. 2024 Apr 14;45(4):351-356. doi: 10.3760/cma.j.cn121090-20231124-00274.
4
Cyclophosphamide-based hematopoietic stem cell mobilization before autologous stem cell transplantation in newly diagnosed multiple myeloma.新诊断多发性骨髓瘤患者自体干细胞移植前基于环磷酰胺的造血干细胞动员
J Clin Apher. 2015 Jun;30(3):176-82. doi: 10.1002/jca.21360. Epub 2014 Oct 8.
5
Single-dose etoposide is an effective and safe protocol for stem cell mobilization in patients with multiple myeloma.单剂量依托泊苷是多发性骨髓瘤患者干细胞动员的一种有效且安全的方案。
J Clin Apher. 2019 Oct;34(5):579-588. doi: 10.1002/jca.21734. Epub 2019 Jul 8.
6
Efficacy of biosimilar granulocyte colony-stimulating factor versus originator granulocyte colony-stimulating factor in peripheral blood stem cell mobilization in de novo multiple myeloma patients.生物类似物粒细胞集落刺激因子与原研粒细胞集落刺激因子在初诊多发性骨髓瘤患者外周血干细胞动员中的疗效比较
Cytotherapy. 2015 Oct;17(10):1485-93. doi: 10.1016/j.jcyt.2015.05.010. Epub 2015 Jul 15.
7
Randomized comparison of granulocyte colony-stimulating factor versus granulocyte-macrophage colony-stimulating factor plus intensive chemotherapy for peripheral blood stem cell mobilization and autologous transplantation in multiple myeloma.粒细胞集落刺激因子与粒细胞巨噬细胞集落刺激因子联合强化化疗用于多发性骨髓瘤外周血干细胞动员和自体移植的随机对照研究
Biol Blood Marrow Transplant. 2004 Jun;10(6):395-404. doi: 10.1016/j.bbmt.2004.02.001.
8
Comparison of two autologous hematopoietic stem cell mobilization strategies in patients with multiple myeloma: CE plus G-CSF versus G-CSF only: A single-center retrospective analysis.两种自体造血干细胞动员策略在多发性骨髓瘤患者中的比较：CE 联合 G-CSF 与仅 G-CSF：一项单中心回顾性分析。
Transfusion. 2024 May;64(5):871-880. doi: 10.1111/trf.17829. Epub 2024 Apr 10.
9
Beyond CD34+ cell dose: impact of method of peripheral blood hematopoietic stem cell mobilization (granulocyte-colony-stimulating factor [G-CSF], G-CSF plus plerixafor, or cyclophosphamide G-CSF/granulocyte-macrophage [GM]-CSF) on number of colony-forming unit-GM, engraftment, and Day +100 hematopoietic graft function.超越 CD34+ 细胞剂量：外周血造血干细胞动员方法（粒细胞集落刺激因子[G-CSF]、G-CSF 加plerixafor 或环磷酰胺 G-CSF/粒细胞-巨噬细胞[GM]-CSF）对集落形成单位-GM 数量、植入和第 100 天造血移植物功能的影响。
Transfusion. 2011 Sep;51(9):1995-2000. doi: 10.1111/j.1537-2995.2011.03085.x. Epub 2011 Mar 10.
10
Plerixafor plus granulocyte colony-stimulating factor versus placebo plus granulocyte colony-stimulating factor for mobilization of CD34(+) hematopoietic stem cells in patients with multiple myeloma and low peripheral blood CD34(+) cell count: results of a subset analysis of a randomized trial.培洛昔福联合粒细胞集落刺激因子与安慰剂联合粒细胞集落刺激因子动员多发性骨髓瘤且外周血 CD34+细胞计数低的患者中的 CD34+造血干细胞：一项随机试验的亚组分析结果。
Biol Blood Marrow Transplant. 2012 Oct;18(10):1564-72. doi: 10.1016/j.bbmt.2012.05.017. Epub 2012 Jun 6.
引用本文的文献
1
The Progress of Autologous Hematopoietic Stem Cell Transplantation in the Treatment of Multiple Myeloma (Review).自体造血干细胞移植治疗多发性骨髓瘤的研究进展（综述）
Technol Cancer Res Treat. 2025 Jan-Dec;24:15330338251321349. doi: 10.1177/15330338251321349. Epub 2025 Mar 25.
2
[Comparison of etoposide combined with G-CSF and cyclophosphamide combined with G-CSF in the mobilization of autologous peripheral blood stem cells in patients with multiple myeloma].依托泊苷联合粒细胞集落刺激因子与环磷酰胺联合粒细胞集落刺激因子用于动员多发性骨髓瘤患者自体外周血干细胞的比较
Zhonghua Xue Ye Xue Za Zhi. 2024 Apr 14;45(4):351-356. doi: 10.3760/cma.j.cn121090-20231124-00274.
本文引用的文献
1
Daratumumab, lenalidomide, bortezomib, and dexamethasone for transplant-eligible newly diagnosed multiple myeloma: the GRIFFIN trial.达雷妥尤单抗、来那度胺、硼替佐米和地塞米松用于适合移植的新诊断多发性骨髓瘤：GRIFFIN 试验。
Blood. 2020 Aug 20;136(8):936-945. doi: 10.1182/blood.2020005288.
2
Cost Effectiveness of Transplant, Conventional Chemotherapy, and Novel Agents in Multiple Myeloma: A Systematic Review.移植、常规化疗和新型药物治疗多发性骨髓瘤的成本效益：系统评价。
Pharmacoeconomics. 2019 Dec;37(12):1421-1449. doi: 10.1007/s40273-019-00828-y.
3
Single-dose etoposide is an effective and safe protocol for stem cell mobilization in patients with multiple myeloma.单剂量依托泊苷是多发性骨髓瘤患者干细胞动员的一种有效且安全的方案。
J Clin Apher. 2019 Oct;34(5):579-588. doi: 10.1002/jca.21734. Epub 2019 Jul 8.
4
Lenalidomide, Bortezomib, and Dexamethasone with Transplantation for Myeloma.来那度胺、硼替佐米与地塞米松联合移植治疗骨髓瘤
N Engl J Med. 2017 Apr 6;376(14):1311-1320. doi: 10.1056/NEJMoa1611750.
5
International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma.国际骨髓瘤工作组多发性骨髓瘤反应和微小残留病评估的共识标准。
Lancet Oncol. 2016 Aug;17(8):e328-e346. doi: 10.1016/S1470-2045(16)30206-6.
6
Contribution of chemotherapy mobilization to disease control in multiple myeloma treated with autologous hematopoietic cell transplantation.化疗动员对接受自体造血细胞移植治疗的多发性骨髓瘤疾病控制的贡献。
Bone Marrow Transplant. 2015 Dec;50(12):1513-8. doi: 10.1038/bmt.2015.190. Epub 2015 Aug 24.
7
Optimizing autologous stem cell mobilization strategies to improve patient outcomes: consensus guidelines and recommendations.优化自体干细胞动员策略以改善患者结局：共识指南和建议。
Biol Blood Marrow Transplant. 2014 Mar;20(3):295-308. doi: 10.1016/j.bbmt.2013.10.013. Epub 2013 Oct 17.
8
Intermediate-dose versus low-dose cyclophosphamide and granulocyte colony-stimulating factor for peripheral blood stem cell mobilization in patients with multiple myeloma treated with novel induction therapies.新型诱导疗法治疗多发性骨髓瘤患者的外周血造血干细胞动员：中剂量与低剂量环磷酰胺和粒细胞集落刺激因子。
Biol Blood Marrow Transplant. 2012 Jul;18(7):1128-35. doi: 10.1016/j.bbmt.2012.01.005. Epub 2012 Jan 14.
9
Etoposide plus G-CSF priming compared with G-CSF alone in patients with lymphoma improves mobilization without an increased risk of secondary myelodysplasia and leukemia.依托泊苷联合 G-CSF 预处理与单独使用 G-CSF 相比，可提高淋巴瘤患者的动员效果，而不会增加继发性骨髓增生异常和白血病的风险。
Bone Marrow Transplant. 2012 Feb;47(2):231-5. doi: 10.1038/bmt.2011.73. Epub 2011 Apr 4.
10
Transplanted CD34(+) cell dose is associated with long-term platelet count recovery following autologous peripheral blood stem cell transplant in patients with non-Hodgkin lymphoma or multiple myeloma.移植的 CD34(+) 细胞剂量与非霍奇金淋巴瘤或多发性骨髓瘤患者自体外周血造血干细胞移植后血小板计数的长期恢复有关。
Biol Blood Marrow Transplant. 2011 Aug;17(8):1146-53. doi: 10.1016/j.bbmt.2010.11.021. Epub 2010 Nov 30.
Zotero 插件